STI
4
-2
ROST
47
-2
TMO
46
2
BXP
46
2
GWW
53
12
ES
26
-3
ABBV
64
-4
MAR
33
-2
GM
65
15
GOOG
55
4
BWA
45
9
ALLE
35
-2
R
61
2
L
60
8
MPC
42
-2
LEN
15
-3
JCI
54
3
HSY
34
2
ZION
64
4
HPQ
37
-9
STI
4
-2
ROST
47
-2
TMO
46
2
BXP
46
2
GWW
53
12
ES
26
-3
ABBV
64
-4
MAR
33
-2
GM
65
15
GOOG
55
4
BWA
45
9
ALLE
35
-2
R
61
2
L
60
8
MPC
42
-2
LEN
15
-3
JCI
54
3
HSY
34
2
ZION
64
4
HPQ
37
-9
Financhill
Back

Esperion Therapeutics 10K Form

Sell
14

ESPR
Esperion Therapeutics

Last Price:
$1.70
Seasonality Move:
3.95%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ESPR News And Ratings

See the #1 stock for the next 7 days that we like better than ESPR

ESPR Financial Statistics

Sales & Book Value

Annual Sales: $332.3M
Cash Flow: $-35M
Price / Cash Flow: 0
Annual Sales: $-1.98
Price / Book: 0

Profitability

EPS (TTM): -0.25000
Net Income (TTM): $-51.7M
Gross Margin: $263.7M
Return on Equity: 0%
Return on Assets: -16.28%

Esperion Therapeutics Earnings Forecast

Key Esperion Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 18 years for ESPR is 79.36%.
  • The Selling, General & Administrative Expenses for ESPR have been equal to 49.07% of Gross Profit Margin.
  • The Research & Development expenses have been 13.91% of Revenue.
  • The Net Earning history of ESPR is -15.57% of Total Revenues.
  • Per Share Earnings over the last 18 years have been positive in 7 years.

Esperion Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ESPR
CUSIP: 29664W
Website: esperion.com

Debt

Debt-to-Equity Ratio: -0.75
Current Ratio: 1.37
Quick Ratio: 0.91

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 277.64

ESPR Technical Analysis vs Fundamental Analysis

Sell
14
Esperion Therapeutics (ESPR) is a Sell

Is Esperion Therapeutics a Buy or a Sell?